07:00 , Jun 1, 2015 |  BioCentury  |  Regulation

Formalizing function

FDA agreed with patients at a workshop on functional GI disorders that patient-reported outcomes measures should tease out the relationship between symptom relief and corresponding quality of life. But doing so presents a catch-22 for...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

RaQualia infectious, neurology, gastrointestinal news

RaQualia said it will reduce headcount by about 12 (14%) to 70 in 2013 to focus on four compounds in early stage development for gastrointestinal diseases. The cuts include the elimination of nine R&D-related positions....
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Gastrointestinal disease Gastroesophageal reflux disease (GERD); gastroparesis...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

Milnacipran: Phase III data

In the double-blind, placebo-controlled, North American Phase III MLN-MD-03 trial in 1,025 subjects with FMS, 100 mg milnacipran met the 2 co-primary endpoints of composite responder criteria. On the first endpoint, significantly more patients experienced...
08:00 , Dec 15, 2008 |  BioCentury  |  Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled...
02:43 , Dec 9, 2008 |  BC Extra  |  Clinical News

Forest, Cypress report milnacipran Phase III data

Forest (NYSE:FRX) and Cypress (NASDAQ:CYPB) said milnacipran met both co-primary composite endpoints in the Phase III MLN-MD-03 trial to treat fibromyalgia syndrome. On the first endpoint, significantly more patients in the milnacipran group experienced >=30%...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Company News

Kosan, Bristol-Myers deal

Simultaneously, Bristol-Myers received an exclusive, worldwide license to Kosan’s epothilone compounds as a backup deal. If the acquisition does not go through, Kosan would receive $25 million up front and be eligible for $400 million...
07:00 , Jun 2, 2008 |  BioCentury  |  Strategy

Kosan Chronicles

Kosan Chronicles Prior to last week's proposed acqusition by Bristol-Myers Squibb, Kosan had been trading at an all-time low of about $1.50 per share. Selected events tracked against Kosan's weekly stock price since the company sold...
07:00 , Jun 2, 2008 |  BioCentury  |  Strategy

String of Pearls

In early 2007, Bristol-Myers Squibb Co. concluded it needed to give itself a dose of strong medicine if it were to survive and prosper. This meant doing a serious assessment of where it could be...
07:00 , May 19, 2008 |  BioCentury  |  Emerging Company Profile

Cempra: Binding bacteria better

Using a set of in-licensed macrolide chemistry technologies, Cempra Pharmaceuticals Inc. is developing a pipeline of macrolide antibiotics that it hopes will be effective against resistant bacteria but have safety profiles similar to marketed macrolides....